# Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

> **NCT05446870** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 160 (actual)

## Conditions studied

- High-grade Serous Ovarian Carcinoma
- Ovarian Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **BIOLOGICAL:** Avastin
- **BIOLOGICAL:** MK-4830
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05446870
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-25
- **Primary completion:** 2023-12-20
- **Final completion:** 2024-10-16
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05446870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05446870, "Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05446870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*